Antibody Humanisation and Affinity Maturation
OXGENE conducts bioinformatic analysis, codon optimisation, DNA synthesis, and antibody production and purification in house. Our software assisted design process is based on in depth expertise and experience. It generates a custom-picked selection of variants using our comprehensive vector toolkit and proprietary antibody template database.
We then use our integrated MHC class II binding prediction and manufacturability analysis to identify liabilities to remove during the process. The variants generated are expressed and purified using OXGENE’s automated high throughput platform, in our proprietary HEK293 EBNA suspension cell line.
We can then use our SLIM display platform to screen affinity maturation libraries to improve the affinity and biophysical properties of a low affinity antibody.
Complex gene edits and target validation
Following a SLIM display discovery or affinity maturation campaign, we can also deploy our automated gene editing platform to support your validation campaigns, for example through the generation of clonal knock-out cell lines or complex disease models.
With the support of our automated gene editing platform, our in-house experts generate clonal cell lines modelling complex disease scenarios, including double knock-outs, conditional knock-outs, knock-ins, gene fusions and chromosomal rearrangements.
We’ve also optimised our automated gene editing platform to accommodate high throughput edits of inducible Pluripotent Stem Cells (iPSCs). These are a particularly powerful tool for disease modelling and drug discovery, but can be challenging to work with, as they differentiate in response to cellular stress, and exhibit notoriously low editing efficiency. However, we’ve optimised our gene editing workflow to achieve a careful balance between cellular stability and editing efficiency to deliver reliably edited iPSC lines.